🇺🇸 FDA
Patent

US 12304968

T-cells expressing anti-LIV1 chimeric antigen receptor

granted A61KA61K2039/812A61K2039/868

Quick answer

US patent 12304968 (T-cells expressing anti-LIV1 chimeric antigen receptor) held by CRISPR THERAPEUTICS AG expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/812, A61K2039/868, A61K2239/49, A61K2239/56